Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis
Bevacizumab-based combinations demonstrate consistent benefits across multiple regimens for PROC. Paclitaxel + bevacizumab emerges as the optimal balance of efficacy and safety. Topotecan + sorafenib could be an alternative for patients who are ineligible for anti-angiogenic therapy.
Authors
- Tianshu Ying (ORCID: https://orcid.org/0009-0005-4242-7867)
- E. Shaolong
- Huanchun Ying
Institutions
- China Medical University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1080/07853890.2026.2624215
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00